Dr. Simi Paknikar's Profile

MD Pharmacology

Dr. Simi Paknikar

Dr. Simi Paknikar is an MD in Pharmacology with professional experience of over a decade, that includes medical writing, teaching and conducting quality audits for medical services companies. Dr Paknikar is passionate about educating consumers about health and keeps abreast of the latest medical research. She contributes by editing and reviewing articles as well as writing on various health topics.

Written / Edited / Medically Reviewed

World Pancreatic Cancer Day 2017: Demand Better. For Patients. For Survival

World Pancreatic Cancer Day 2017: Demand Better. For Patients. For Survival

The World Pancreatic Cancer Day is being celebrated on November 16, 2017, aims to early diagnosis and improve outcomes for the patient.

Health Watch
Ozanimod Shows Positive Response in Relapsing Multiple Sclerosis in Two Clinical Trials

Ozanimod Shows Positive Response in Relapsing Multiple Sclerosis in Two Clinical Trials

Two phase 3 clinical trials indicate better efficacy and safety of ozanimod for the treatment of relapsing multiple sclerosis.

Health In Focus
Somatoform Disorders

Somatoform Disorders

Somatic symptom disorder is said to occur when a person’s focus, feelings and behavior related to physical symptoms is excessive and affects normal functioning.

Disease & Condition
Combination Targeted Therapies may Improve Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC)

Combination Targeted Therapies may Improve Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-small cell lung cancers show genetic changes during treatment with targeted therapy; combination targeted therapies or regular monitoring of genetic changes during treatment may be required.

Health In Focus
Acalabrutinib Receives‘Breakthrough Therapy Designation’in Mantle Cell Lymphoma

Acalabrutinib Receives‘Breakthrough Therapy Designation’in Mantle Cell Lymphoma

Acalabrutinib,a Bruton tyrosine kinase(BTK) inhibitor, has received the ‘Breakthrough Therapy Designation’from the US FDA for the treatment of relapsed or non-responding cases of mantle cell lymphoma.

Health In Focus